普伐他汀预防HELLP综合征：一例报告。
Pravastatin for prevention of HELLP syndrome: A case report.
作者信息
Otten Lucia Anna, van der Ven Katrin, Kühr Marietta, Gembruch Ulrich, Merz Waltraut Maria
机构信息
Department of Obstetrics and Prenatal Medicine Department of Gynecologic Endocrinology and Reproductive Medicine, University Bonn Medical School, Bonn, Germany.
出版信息
Medicine (Baltimore). 2017 Oct;96(42):e8229. doi: 10.1097/MD.0000000000008229.
RATIONALE
Pravastatin has emerged for prevention and treatment of preeclampsia; no reports are available on pravastatin and HELLP (hemolysis, elevated liver enzymes and low platelets) syndrome.
PATIENT CONCERNS
The first pregnancy necessitated termination of pregnancy at gestational age (GA) 20+5 for HELLP. Intrauterine fetal death at GA 22+5 occurred in the second pregnancy, whilst on temporizing management of HELLP.
DIAGNOSES
Severe, recurrent early-onset HELLP syndrome.
INTERVENTIONS
In her fourth pregnancy, pravastatin was commenced at GA 13.
OUTCOMES
The course of pregnancy was uncomplicated, and a healthy, appropriate for gestational age fetus was delivered at term.
LESSONS
Pravastatin may be effective in prevention of HELLP. The hepatic uptake may be of particular advantage.
理论依据
普伐他汀已用于子痫前期的预防和治疗；目前尚无关于普伐他汀与HELLP（溶血、肝酶升高和血小板减少）综合征的报道。
患者情况
首次怀孕因HELLP在孕20⁺⁵周时终止妊娠。第二次怀孕在对HELLP进行临时处理期间，于孕22⁺⁵周发生宫内胎儿死亡。
诊断
重度、复发性早发型HELLP综合征。
干预措施
第四次怀孕时，在孕13周开始使用普伐他汀。
结果
孕期过程顺利，足月分娩出一名健康的适于胎龄儿。
经验教训
普伐他汀可能对预防HELLP有效。肝脏摄取可能具有特别的优势。
Zotero 插件